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ABSTRACT
Eosinophilic fasciitis is an uncommon disorder of unknown aetiology and poorly-understood patho-
genesis. Since 1974, over 250 cases of eosinophilic fasciitis have been reported worldwide. The first case 
of eosinophilic fasciitis from Bangladesh is reported here. The challenges of diagnosis, treatment, and 
follow-up, including family and social support, are discussed.
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INTRODUCTION
Eosinophilic fasciitis is a rare, localized fibrosing 
disorder of the fascia of unclear aetiology and 
pathophysiology (1). It is associated with peripheral 
eosinophilia, hypergammaglobulinaemia, elevated 
erythrocyte sedimentation rate, erythema, swell-
ing, induration of the extremities, and no visceral 
changes (2). In 1974, Shulman provided an early 
description of eosinophilic fasciitis as a disorder   
characterized by peripheral eosinophilia and fas-
ciitis that could be differentiated from scleroderma 
by the distinctive pattern of skin involvement that 
spares the digits, involves the fascia rather than 
dermis, and is not accompanied with the Raynaud 
phenomenon (3). Biopsy showed a conspicuous 
thickening of the fascia between the subcutis and 
the muscle, with an intense infiltration of lym-
phocytes and plasma cells and a good response to 
corticosteroid therapy, suggesting that this was a 
distinct rheumatic disease syndrome. Based on the 
striking histological changes in the subcutaneous 
fascia, Rodnan proposed that this condition be 
termed ‘eosinophilic fasciitis’ (1). Since 1974, over 
250 patients with eosinophilic fasciitis have been 
reported worldwide (4). 
CASE REPORT
A 40-year-old non-hypertensive mother (house-
wife) of three children was admitted to the Banga-
bandhu Sheikh Mujib Medical University, a terti-
ary-care hospital in Dhaka, in 2008. About a year 
prior to hospitalization, the patient first noticed 
itchy reddish localized swelling in the medial as-
pect of the right forearm. She described her symp-
toms as a feeling of an insect moving within it and 
felt some comfort when hot compression was used. 
Four months after the onset of the illness, she no-
ticed blackish pigmentation at the margin of the le-
sion with profound itching. The lesion progressed 
and involved the wrist to the lower part of the 
right arm. The patient also noticed numbness in 
the whole right arm with pain and tightness. Due 
to lack of improvement, her general physician pres-
cribed betamethasone tablet (0.5 mg) three times 
daily. With betamethasone, the patient noticed 
remarkable improvement in terms of reduction in 
pain and pigmentation over four months. Howev-
er, she developed generalized swelling of the body, 
for which she was hospitalized for further evalua-
tion. 
On admission, other than swelling of the whole 
body, she complained of generalized aches and 
weakness. There were no symptoms to suggest pul-
monary, renal, cardiac or gastrointestinal involve-
ment. Her past medical history was unremarkable, Islam MN et al.
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and none of her family members was suffering 
from any disease of connective tissues. She came 
from a lower middle-class family and lived in a 
second class government staff quarter. She did not 
give any history of smoking, tobacco-use, or intake 
of alcohol. On examination, the pulse rate was 96 
beats per minute; blood pressure was 115/75 mm 
Hg; and she had a puffy face and mild pedal oede-
ma. Diffuse blackish pigmentation was seen over 
the anterior aspect of her both upper limbs, more 
on right arm, palmar creases, and knuckle of the 
fingers. Muscle power was 4/5 in proximal mus-
cles of all limbs. There was moderate tenderness in 
the second, third, fourth, and fifth proximal and 
distal interphalangeal and metacarpal joints. Her 
forearms were tight, grooving over the attachment 
of fascia, more marked on the right side. From her 
presentation, possibilities of eosinophilic fasciitis, 
scleroderma, and the eosinophilia-myalgia syn-
drome were suspected. Examination of her com-
plete blood count showed a marked eosinophilia 
(Table). Her blood sugar, liver and kidney function 
tests were normal. A skin biopsy was reported as 
follows: “atrophic epidermis; dermis reveals thick 
bundles of collagen with atrophied adnexa. The 
papillary dermis shows infiltration of chronic in-
flammatory cells and melanophages. Infiltration 
of eosinophil, lymphocytes, polymorph, and mast 
cells was noted in the subcutaneous tissue. The 
features are compatible with scleroderma”. Subse-
quently, a muscle biopsy was done. Its microscopic 
appearance showed skeletal muscle and fascia. 
The fascia was thick due to oedema and fibrosis. 
There was a moderate infiltrate of lymphocytes, 
eosinophil mixed with a small number of histio-
cytes, and plasma cells. The features were compati-
ble with eosinophilic fasciitis. In both the biopsies, 
direct immunofluorescence showed no deposition 
of immunoglobulins (IgM, IgA, IgG), C3, or fibrino-
gen. Serological markers, such as serum creatine 
kinase (CK), anti-Scl 70, anti-centromere antibody, 
rheumatoid factor, and antinuclear antibody, were 
negative. The serum immunoglobulin levels were 
within the normal range. Her ECG, PA view of chest 
x-ray, AP and lateral view x-ray of lumbar spines, 
and ultrasonography of the whole abdomen were 
normal. Initially, her serum alanine transaminase 
was 64 U/L, which later became 15 U/L, and serum 
creatinine was 1 mg/dL.
She was discharged with oral prednisolone 20 mg 
daily in the morning, hydroxychloroquine 200 mg 
twice daily, calcium carbonate 500 mg twice daily, 
and vitamin D3 200 IU twice daily, with a follow-
up schedule at an interval of 4-6 weeks for three 
months and then three-monthly. 
The response to treatment was remarkable. The 
eosinophil count came down to normal with relief 
of pain and improvement in the tightening of the 
skin. Noting improvement, steroids were reduced 
by 2.5 mg per week. An eosinophil count of less 
than 10% was achieved with 10 mg prednisolone 
daily. Further reduction to 7.5 mg failed to main-
tain the eosinophil count at 10%. So, she was kept 
on 10 mg prednisolone daily as a maintenance 
dose. Subsequently, the patient was irregular in fol-
low-up. 
After about two years, she noticed gain in weight 
and nocturnal polyuria. On evaluation, her fast-
ing blood glucose was 7.8 mmol (Table), and she 
was diagnosed as a case of type II diabetes mellitus, 
for which oral anti-diabetic agents with lifestyle 
modification, including diet and exercise, were 
prescribed. Ultimately, 10 mg prednisolone was 
enough to maintain the eosinophil count near nor-
mal but good glycaemic control remained a prob-
lem with oral anti-diabetic agents. She continued 
taking hydroxychloroquine at a dose of 200 mg 
b.i.d with no ocular problem/toxicity.
Table. Total and differential counts of WBC and blood glucose at different visits
Test 10.08.08 26.09.08 12.11.08 15.01.09 21.04.09 28.08.09 27.05.10 11.09.10 08.01.11
ESR: mm 
in 1st hour 28 25 - 25 40 15 45 15 25
TC WBC 
(x 109/L) 17.1 10 10 8 9.5 10 9 9.5 9.3
DC WBC (%)       
Eosinophil  36 50 08 02 12 04 10 07 18
  FBS
  (mmol/L)




















AFB=After breakfast; DC=Differential count; ESR=Erythrocyte sedimentation rate; FBS=Fasting blood 
sugar; TC=Total count; WBC=White blood cellIslam MN et al. Eosinophilic fasciitis
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In subsequent follow-up, she described family dis-
harmony and developed hypertension. At that 
stage, she became more irregular in routine follow-
up and refused to take any additional medicine 
because of financial constraints, lack of family sup-
port, and profound depression. 
DISCUSSION
Eosinophilic fasciitis is a scleroderma-like syndrome 
of unknown cause characterized by inflammation, 
followed by sclerosis of the dermis, subcutis, and 
deep fascia. The disease affects adults. Patients usu-
ally have an abrupt onset of symmetrical tenderness 
and swelling of the extremities, rapidly followed 
by induration of the skin and subcutaneous tissue 
without Raynaud’s phenomenon. Carpal tunnel 
syndrome and low-grade myositis with normal cre-
atine kinase and flexion contractures may develop 
later. A marked eosinophilia is found in the early 
stage of the disease and subsequently decreases. 
A full thickness biopsy, consisting of skin, fascia, 
and superficial muscle, shows perivascular infiltra-
tion of histiocytes, eosinophils, lymphocytes, and 
plasma cells. The spontaneous improvement and 
occasionally complete remission might occur af-
ter 2-5 years of disease. Some patients suffer from 
persistent disease while others are left with flex-
ion contractures (5). The majority of patients with 
eosinophilic  fasciitis  have  peripheral  blood  eosi-
nophilia during the acute phase of disease. In one 
series, 33 of 52 patients had eosinophilia (6) and 
elevated erythrocyte sedimentation rate (29%), and 
polyclonal hypergammaglobulinaemia (35%) can 
also be found (7). Antinuclear antibody positivity 
has not been reported previously in eosinophilic 
fasciitis with any consistency, and rheumatoid fac-
tor is almost always negative. Definitive diagnosis 
requires histopathological examination from a full-
thickness (epidermis to muscle) biopsy (8).
The presentation of this patient with itchy reddish 
and swollen skin lesion was not typical of eosi-
nophilic fasciitis at the beginning, leading to a rea-
sonable delay in diagnosis, especially as it is a rare 
disease. During the course of her illness, evolving 
features, especially peripheral eosinophilia, pro-
voked the possibility of a diagnosis of eosinophilic 
fasciitis. The course of her illness was progressive, 
resulting in marked tightening of the skin and 
subsequent impairment of joint mobility. An evi-
dent groove sign in skin and absence of Raynaud’s 
phenomenon were striking. The disease spared her 
face, hands, and feet. Her antinuclear antibody and 
rheumatoid factor test was negative. Full-thickness 
biopsy (epidermis to muscle) was consistent with 
diagnosis. 
The spontaneous remission rate in patients with 
eosinophilic fasciitis is 10-20% from the time of 
presentation or relapse after discontinuing corti-
costeroid therapy (9). In one series, haematologi-
cal disorders other than eosinophilia were present 
in 5 of 52 patients (7). Haematological abnormali-
ties that have been described, in association with 
eosinophilic fasciitis, include aplastic anaemia, 
acquired amegakaryocytic thrombocytopaenia, 
myeloproliferative disorders, myelodysplastic syn-
dromes, lymphoma, leukaemia, and multiple my-
eloma (7). However, there was no haematological 
abnormality in our patient. There is substantial 
agreement among published cases and case series 
that corticosteroids are the first-line treatment for 
eosinophilic fasciitis and are usually effective in 
over 70% of cases. Other treatments include non-
steroidal anti-inflammatory drugs, D-penicilla-
mine, chloroquine, cimetidine, methotrexate, aza-
thioprine, cyclosporine A, infliximab, UVA-1, and 
bath PUVA (10,11). 
Lakhanpal et al. reported 52 cases of Raynaud’s phe-
nomenon, and only 59% of them had a satisfac-
tory response to prednisolone alone (40-60 mg/day 
in divided daily doses) (12). Abnormalities found 
through laboratory tests, including elevated eryth-
rocyte sedimentation rate, peripheral eosinophilia, 
and hypergammaglobulinaemia, reverted to nor-
mal with prednisolone therapy in most patients 
(12). However, corticosteroid resistance has been 
encountered in the setting of paraneoplastic and 
in-graft versus host disease (13).
Response to steroid and hydroxychloroquine was 
good in our case but a low dose of prednisolone (10 
mg) was needed to maintain an eosinophil count 
of less than 10%. The patient developed diabetes 
and hypertension after about two years of taking 
steroid. While taking steroid, she needed glimepi-
ride 4 mg per day to manage diabetes. She became 
partly refractory to ongoing treatment and devel-
oped two more co-morbid illnesses most likely due 
to the steroid. At the end, her long suffering and co-
morbidities resulted in family disharmony, and she 
became profoundly depressed. She refused further 
medication and was lost to follow-up. 
Eosinophilic fasciitis can present with various 
symptoms. A strong suspicion and a proper ap-
proach help in its early diagnosis. In a developing 
country like Bangladesh, rheumatology gets little 
space in the graduate curriculum, and a graduate 
gets little or no exposure to most common rheu-
matic illnesses during his/her studies. Chronic 
and rare rheumatic illnesses need a strong index 
of suspicion that can only be achieved through 
training, refresher courses, and easy access to medi-
cal journals. In Bangladesh, there is no training 
programme to update our graduate practitioners, Islam MN et al.
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and there is no central system of accessing medi-
cal publications by our health practitioners. The 
injudicious use of steroids is an issue among our 
physicians due to the lack of knowledge and aware-
ness, and this blurred the clinical presentation of 
the disease in our case, leading to a further delay in 
accurate diagnosis. Patients often continue taking 
steroids without following the instructions of their 
physicians, i.e. they do it by self-prescribing, due 
to their comfort. Besides, drugs are easily available 
from pharmacies.  
Chronic illnesses are now a major health issue in 
both developed and developing countries. Many 
chronic illnesses are expensive to manage, and this 
is often the greatest barrier to their management 
(14). People who fall ill often face a dire choice: ei-
ther to suffer death without treatment or to seek 
treatment and push their family into poverty (15). 
This patient could have been better managed by 
agents, such as azathioprine, methotrexate, and 
cyclosporine, with no impact on blood sugar; how-
ever, all are costly (azathioprine and cyclosporine) 
due to price and follow-up laboratory tests (metho-
trexate and cyclosporine). In developing coun-
tries like Bangladesh, households often sell their 
possessions to cover healthcare costs, particularly 
when chronic diseases require long-term costly 
treatment (16). Supporting family members who 
live with chronic illness requires recognition of the 
complexity of the illness experience and the nature 
of social support (17). 
Conclusion
We recommend mass awareness and familial, so-
cial and government support to manage chronic 
rheumatic diseases reported in this study.
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